MapLight shares sink on mixed ph. 2 schizophrenia readout
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"MapLight shares sink on mixed ph. 2 schizophrenia readout" is generating significant coverage in the Business category, with 8 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, BioWorld News, BioPharma Dive and simplywall.st. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 49d ago.
Quick answers
Why is "MapLight shares sink on mixed ph. 2 schizophrenia readout" trending?
Because 7 independent news sources published 8 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint Yahoo Finance · 52d ago
- MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose Yahoo Finance · 52d ago
- Maplight aims to differentiate muscarinic agonist from competitors BioWorld News · 52d ago
- MapLight dives despite positive data for schizophrenia drug BioPharma Dive · 52d ago
- MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus simplywall.st · 52d ago
- Biotech And AI Stocks Got Hit On Mixed News Finimize · 52d ago
- Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia Psychiatric Times · 52d ago
- MapLight shares sink on mixed ph. 2 schizophrenia readout Fierce Biotech · 52d ago
Topics
Related trends
Starbucks resolves Florida DEI lawsuit with blockbuster nationwide agreement
Paramount-Warner Bros. Discovery Merger Clears FCC Foreign Ownership Review
Meta Muse May Be Biggest AI Launch Since ChatGPT. It’s Just One of Many Catalysts for Meta Stock.
Arizona grocer stops selling popular energy drink. Here's why
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Starbucks agrees to DEI overhaul after blockbuster Florida legal showdown
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.